Clinical and laboratory characteristics of patients with AIHA at enrollment and treatment outcome
| Characteristic . | Patients (N = 54) . |
|---|---|
| Age, median (range), y | 66 (20-90) |
| Sex, n (%) | |
| Female | 32 (59) |
| Male | 22 (41) |
| AIHA type, n (%) | |
| wAIHA IgG | 23 (42.6) |
| wAIHA IgG+C | 4 (7.4) |
| Cold | 20 (37) |
| Mixed | 4 (7.4) |
| Atypical | 3 (5.6) |
| Hemoglobin, median (range), g/dL | 9.6 (4.4-13.2) |
| LDH × ULN, median (range) | 1.36 (0.5-4.5) |
| Unconjugated bilirubin, median (range), mg/dL | 1.72 (0.4-9.7) |
| Reticulocytes, median (range), ×109/L | 145 (27-550) |
| IgA, median (range), g/L | 137 (42-385) |
| IgG, median (range), g/L | 681 (401-1014) |
| IgM, median (range), g/L | 110 (32-303) |
| Time to LD rituximab, median (range), mo | 7 (0-89) |
| Prospective follow-up, median (range), mo | 53 (6-120) |
| Month +2 ORR/CR, n (%) | 46 (85)/25 (46) |
| Month +6 ORR/CR, n (%) | 35 (83)/26 (62) |
| Month +12 ORR/CR, n (%) | 30 (88)/23 (68) |
| Month +18 ORR/CR, n (%) | 20 (91)/15 (68) |
| Month +24 ORR/CR, n (%) | 18 (95)/15 (79) |
| Month +36 ORR/CR, n (%) | 8 (89)/6 (67) |
| Duration of response, median (range), mo | 15 (3-85) |
| RFS, median (range), mo | 41.9 (14.3-69.5) |
| Relapsed, n (%) | 28 (62) |
| Characteristic . | Patients (N = 54) . |
|---|---|
| Age, median (range), y | 66 (20-90) |
| Sex, n (%) | |
| Female | 32 (59) |
| Male | 22 (41) |
| AIHA type, n (%) | |
| wAIHA IgG | 23 (42.6) |
| wAIHA IgG+C | 4 (7.4) |
| Cold | 20 (37) |
| Mixed | 4 (7.4) |
| Atypical | 3 (5.6) |
| Hemoglobin, median (range), g/dL | 9.6 (4.4-13.2) |
| LDH × ULN, median (range) | 1.36 (0.5-4.5) |
| Unconjugated bilirubin, median (range), mg/dL | 1.72 (0.4-9.7) |
| Reticulocytes, median (range), ×109/L | 145 (27-550) |
| IgA, median (range), g/L | 137 (42-385) |
| IgG, median (range), g/L | 681 (401-1014) |
| IgM, median (range), g/L | 110 (32-303) |
| Time to LD rituximab, median (range), mo | 7 (0-89) |
| Prospective follow-up, median (range), mo | 53 (6-120) |
| Month +2 ORR/CR, n (%) | 46 (85)/25 (46) |
| Month +6 ORR/CR, n (%) | 35 (83)/26 (62) |
| Month +12 ORR/CR, n (%) | 30 (88)/23 (68) |
| Month +18 ORR/CR, n (%) | 20 (91)/15 (68) |
| Month +24 ORR/CR, n (%) | 18 (95)/15 (79) |
| Month +36 ORR/CR, n (%) | 8 (89)/6 (67) |
| Duration of response, median (range), mo | 15 (3-85) |
| RFS, median (range), mo | 41.9 (14.3-69.5) |
| Relapsed, n (%) | 28 (62) |
wAIHA direct antiglobulin test result positive for IgG only (wAIHA IgG) and wAIHA direct antiglobulin test result positive for IgG and low-titer C (wAIHA IgG+C) types included 14 cases from the pilot study and an additional 13 cases; CAD included 9 and 11 patients, respectively. Four mixed and 7 atypical AIHA cases were all newly treated in this study. LDH, lactate dehydrogenase; ULN, upper limit of normal.